Showing 1351-1360 of 3553 results for "".
10 Things Dermatologists Need to Know About Treating Vitiligo Today
https://practicaldermatology.com/topics/pigmentary-disorders/10-things-dermatologists-need-to-know-about-treating-vitiligo-today/22988/New and emerging treatment approaches offer hope for this challenging condition.Dumbing Down of Dermatology By Evidence-Based Medicine
https://practicaldermatology.com/topics/practice-management/how-do-you-make-this-do-that/20593/Five Tips for Long-Term Success
https://practicaldermatology.com/topics/practice-management/five-tips-for-long-term-success/20451/Clascoterone: A Novel Topical Anti-androgen for the Treatment of Acne
https://practicaldermatology.com/columns/clinical-focus-1/clascoterone-a-novel-topical-anti-androgen-for-the-treatment-of-acne/23133/For the first time in almost 15 years, a new chemical entity may be coming to the market for the topical treatment of acne vulgaris.Four Ways to Ease the Burden of Prior Authorization
https://practicaldermatology.com/topics/practice-management/four-ways-to-ease-the-burden-of-prior-authorization/20434/There's no way around PAs, but it is possible to make the process more manageable.Ease On Down The Road: Getting Started with MIPS
https://practicaldermatology.com/topics/practice-management/ease-on-down-the-road-getting-started-with-mips/20734/Part one of a three-part series on the MIPS “pick-your-pace” transition.State Legislation of EHRs: A Sweeping Precedent?
https://practicaldermatology.com/topics/practice-management/state-ehr-legislation-a-new-precedent/21483/A new law in Massachusetts requires all licensed physicians to be using an EHR by 2015.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21848/GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muReflections On a Year Unlike Any Other
https://practicaldermatology.com/topics/practice-management/reflections-on-a-year-unlike-any-other/23398/Change is good and other hard lessons from 2020.